RxDoctor Payments Data

Jeffrey Roth, OD

Optometrist · Syracuse, NYNPI 1437196631

Payments from drug & device makers

$749in general payments, 2019–2025

Across 37 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$197
  • Sun Pharmaceutical Industries Inc.$102
  • Tarsus Pharmaceuticals, Inc.$66
  • Johnson & Johnson Surgical Vision, Inc.$54
  • Johnson & Johnson Vision Care, Inc.$52
  • Oyster Point Pharma, Inc.$48
  • plus $230 from 9 others

What the payments were for

  • Food & beverage$73097%
  • Gifts$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$749 in reported general payments places this provider in the 55th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$138,842
Medicare patients
644
Services billed
2,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost60$45,253
RestasisCyclosporine31$39,078
XiidraLifitegrast24$23,779
MieboPerfluorohexyloctane/Pf28$20,576
CequaCyclosporine13$11,476
VyzultaLatanoprostene Bunod25$8,061
SimbrinzaBrinzolamide/Brimonidine Tart12$4,519
Travoprost20$3,212
Latanoprost271$2,983
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat134$2,695
Bimatoprost14$2,670
Loteprednol Etabonate13$2,514
Prednisolone Acetate48$2,380
Tobramycin-DexamethasoneTobramycin/Dexamethasone33$1,223
Timolol Maleate28$1,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$34$84,33191 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$39$52,41677 claims
Sun Pharmaceutical Industries Inc.Cequa$102$11,47613 claims
AlconSimbrinza$197$4,51912 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$27$2,51413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,743 optometrist providers in New York.

Other optometrist in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →